Management of INR 3.2 in Chronic Atrial Fibrillation
Continue the current warfarin dose without adjustment and recheck the INR in 1-2 weeks.
Rationale for No Dose Change
Your patient's INR of 3.2 represents a single, minimally elevated value (only 0.2 above the therapeutic range of 2.0-3.0). The American College of Chest Physicians (ACCP) guidelines specifically address this scenario and recommend continuing the current dose for single out-of-range INRs within 0.5 of the therapeutic target 1.
The evidence supporting this approach is compelling:
An observational study specifically evaluated INRs of 3.2-3.4 in patients with a target range of 2.0-3.0. When the dose was continued (78% of the time in anticoagulation management services), no major bleeding or thromboembolic events occurred during 14-30 days of follow-up 1.
An RCT comparing dose adjustments versus continuing the same dose for INRs between 1.5-4.4 found no difference in outcomes at 2-week follow-up (44% vs 40% remained out of range, OR 1.17,95% CI 0.59-2.30, p=0.75) 1.
A dosing model from 3,961 patients suggested warfarin doses do not need adjustment for INRs between 1.7-3.3 1.
Clinical Context
Your patient's trajectory shows stability:
- Previous INR: 2.9 (therapeutic)
- Current INR: 3.2 (minimally elevated)
- This represents a small, likely transient fluctuation of 0.3 units
This pattern suggests the current dose is appropriate, and the slight elevation may reflect normal INR variability rather than true overanticoagulation.
Monitoring Plan
Recheck INR in 1-2 weeks to exclude progressive deviation from therapeutic range 1. This interval allows you to:
- Confirm whether this is an isolated fluctuation
- Detect any upward trend requiring intervention
- Avoid unnecessary dose adjustments that could destabilize previously good control
Important Caveats
Do not continue the current dose if:
- The patient has bleeding symptoms (even minor)
- There are new medications or dietary changes affecting warfarin metabolism
- The patient has had multiple consecutive INRs trending upward
- The INR continues rising above 3.5 on repeat testing
Consider a small dose reduction (5-10% of weekly dose) only if the next INR remains >3.2 or shows further elevation 2.
Why Dose Changes Can Be Counterproductive
Making dose adjustments for minimally elevated INRs often leads to:
- Overcorrection with subsequent subtherapeutic INRs
- INR instability that increases both thrombotic and bleeding risks 3, 4
- Unnecessary testing burden requiring more frequent monitoring
The 2022 study from the Michigan Anticoagulation Quality Improvement Initiative found that while dose changes had a statistically higher probability of achieving therapeutic INR (60.0% vs 58.9%, p=0.024), this 1.1% difference is clinically insignificant and supports watchful waiting 5.
Target INR Confirmation
For chronic atrial fibrillation, the target INR is 2.0-3.0 6, 7. Your patient's INR of 3.2 is only marginally above this range and does not warrant immediate intervention in the absence of bleeding.